Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Metab Dispos ; 41(4): 774-84, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23318685

ABSTRACT

Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. Studies were designed to determine the erythropoietic response, pharmacokinetics (PK), tissue distribution, metabolism, and excretion of peginesatide in nonhuman primates following a single i.v. dose. The PK profile of peginesatide (0.1-5 mg/kg) is characterized by low, dose-dependent plasma clearance; small volume of distribution; and long half-life. The peginesatide PK profile following a single i.v. dose is consistent with the sustained erythropoiesis. Biodistribution quantitative whole-body autoradiography demonstrated high peginesatide levels in bone marrow (i.e., primary hematopoietic site) as well as other known hematopoietic sites persisting through at least 3 weeks at 2.1 mg/kg. Microautoradiography analysis at 48 hours postdose revealed uniform and high distribution of radioactivity in the bone marrow and splenic red pulp with less extensive distribution in the renal cortex (glomeruli, associated ducts, interstitial cells). Radioactivity in the kidney was most prominent in the outer medullary and papillary interstitium. At 2 weeks after dosing, cumulative radioactivity recovery in the urine and feces was 60 and 7% of the administered dose, respectively, with most of the radioactivity associated with the parent molecule. In conclusion, the PK characteristics are consistent with a PEGylated peptide of a 45-kDa molecular mass, specifically low volume of distribution and long half-life. Drug was localized principally to hematopoietic sites, and nonspecific tissue retention was not observed. The nonhuman primate data indicate that peginesatide is metabolically stable and primarily excreted in the urine.


Subject(s)
Hematinics/administration & dosage , Hematinics/pharmacokinetics , Peptides/administration & dosage , Peptides/pharmacokinetics , Administration, Intravenous , Animals , Biological Availability , Bone Marrow/diagnostic imaging , Bone Marrow/metabolism , Dose-Response Relationship, Drug , Erythropoiesis/drug effects , Hematinics/metabolism , Hematinics/pharmacology , Kidney/diagnostic imaging , Kidney/metabolism , Macaca fascicularis , Male , Peptides/metabolism , Peptides/pharmacology , Radionuclide Imaging , Spleen/diagnostic imaging , Spleen/metabolism
2.
Vet Ther ; 11(4): E1-10, 2010.
Article in English | MEDLINE | ID: mdl-21308663

ABSTRACT

To investigate the cutaneous distribution, localization, and persistence of imidacloprid in dogs, Advantage Topical Solution labeled with carbon 14 ((14)C) was topically applied as a single treatment at label rates and application pattern based on body weight to two adult beagles. One dog (8.5 kg) received 1.0 mL of the test solution at a single spot in the interscapular area (14 mg active ingredient/kg body weight); the second dog (12.3 kg) was treated with 2.5 mL of the test solution at four sites, each site receiving approximately 0.625 mL, along the dorsal thoracic and lumbar spine area (21 mg active ingredient/kg body weight). Samples of hair, skin surface residue, and skin taken from the application sites and/or distal body regions of the dogs at four intervals between 7 and 56 days after treatment demonstrated the migration of (14)C radioactivity from the application sites to distal areas of the canine haircoat and skin. The (14)C radioactivity concentrations in the skin biopsy and stratum corneum samples diminished steadily over 56 days after treatment. Microautoradiography of the skin showed focal concentrations of radioactivity in the superficial epidermis, hair follicles, and sebaceous glands. The presence of imidacloprid-derived radioactivity within hair follicles and sebaceous glands and on the skin surface is in good agreement with the reported efficacy of imidacloprid against fleas on dogs and cats for up to 1 month despite posttreatment bathing, shampooing, and/or swimming.


Subject(s)
Dogs/metabolism , Imidazoles/pharmacokinetics , Insecticides/pharmacokinetics , Nitro Compounds/pharmacokinetics , Skin/metabolism , Administration, Topical , Animals , Female , Imidazoles/administration & dosage , Insecticides/administration & dosage , Male , Neonicotinoids , Nitro Compounds/administration & dosage , Skin/chemistry , Tissue Distribution
3.
Bioorg Med Chem Lett ; 13(3): 533-8, 2003 Feb 10.
Article in English | MEDLINE | ID: mdl-12565966

ABSTRACT

Based on the realization that N-alkyl 5-arylidene-2-thioxo-1,3-thiazolidin-4-ones are tumor necrosis factor-alpha antagonists, we discovered two additional classes of antagonists: 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones (via rational design) and 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones (via computer-guided screening). Chemical modification of the lead structures showed that the structure-activity relationship profiles for both of these series were dependent on the electronic properties of the molecules. Subsequent studies showed that they were light-dependent inhibitors.


Subject(s)
Indoles/chemical synthesis , Indoles/pharmacology , Pyrimidines/chemical synthesis , Pyrimidines/pharmacology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Animals , CD40 Antigens/metabolism , CHO Cells , Cricetinae , Drug Design , Electrochemistry , Indicators and Reagents , Light , Structure-Activity Relationship , Tumor Necrosis Factor-alpha/radiation effects
SELECTION OF CITATIONS
SEARCH DETAIL
...